01Jun
10May
Platelet BioGenesis Licenses Induced Pluripotent Stem Cell Technology from iPS Academia Japan
Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+™) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale. Read more >>
10May
Platelet BioGenesis Licenses Induced Pluripotent Stem Cell Technology from iPS Academia Japan
Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+™) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale. Read more >>
21Dec
iCons Works at Fall Workshop
About 100 iCons scholars and applicants gathered in the Integrative Learning Center of UMass Amherst on Nov 9, 2017 for the annual iCons Fall Integrative Workshop. They came to hear Dr. Jonathan Thon tell the story of how his start-up company Platelet Biogenesis came to be. Integrated Concentration in Science (iCons) Program Director Justin Fermann introduced Thon to the crowd, telling the iCons students “we are here because we have work to do, and he’s got some problems we need...
18Oct
BioPharm America™ 2017: Platelet BioGenesis generating platelets on demand
Platelets are the bandaids of the bloodstream. Every year more than two million people in the US receive platelet transfusions as part of cancer treatment, transplants and surgery. Unfortunately, platelets are at high risk of bacterial or viral contamination, and have a very short shelf life. We spoke to Sven Karlsson of Platelet BioGenesis, an exciting company and winner of the BioPharm America startup competition, that has developed a ex vivo system for generating immune compatible platelets on demand. Read...
09Jun